The vast majority of genetic mutations associated with cancer occur in non-coding regions of the genome, yet it’s unclear how they may influence tumor development or growth. Researchers have identified nearly 200 mutations in non-coding DNA that play a role in cancer. Each mutation could represent a new cancer drug target.